[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[S. 5046 Introduced in Senate (IS)]
<DOC>
118th CONGRESS
2d Session
S. 5046
To require the Secretary of Health and Human Services, acting through
the Commissioner of Food and Drugs, to publish a final rule relating to
nonclinical testing methods.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
September 12, 2024
Mr. Booker (for himself, Mr. Schmitt, Mr. Paul, Mr. King, Mr. Braun,
Mr. Whitehouse, Mr. Kennedy, Mr. Lujan, and Mr. Blumenthal) introduced
the following bill; which was read twice and referred to the Committee
on Health, Education, Labor, and Pensions
_______________________________________________________________________
A BILL
To require the Secretary of Health and Human Services, acting through
the Commissioner of Food and Drugs, to publish a final rule relating to
nonclinical testing methods.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``FDA Modernization Act 3.0''.
SEC. 2. REGULATIONS ON NONCLINICAL TESTING METHODS.
(a) In General.--Not later than 180 days after the date of
enactment of this Act, the Secretary of Health and Human Services,
acting through the Commissioner of Food and Drugs, shall publish a
final rule to implement section 505(z) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 355(z)).
(b) Technical Amendment.--Section 505 of the Federal Food, Drug,
and Cosmetic Act (21 U.S.C. 355) is amended by designating the second
subsection (z) (relating to clinical trial diversity action plans), as
added by section 3601(a) of the Health Extenders, Improving Access to
Medicare, Medicaid, and CHIP, and Strengthening Public Health Act of
2022 (division FF of Public Law 117-328), as subsection (aa).
<all>